Scholar Rock Holding Co. (NASDAQ:SRRK) Given Consensus Rating of "Buy" by Analysts

Shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) have received a consensus rating of "Buy" from the seven research firms that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $40.43.

SRRK has been the topic of a number of analyst reports. JPMorgan Chase & Co. increased their price objective on Scholar Rock from $18.00 to $31.00 and gave the company an "overweight" rating in a report on Monday, October 14th. Wedbush reaffirmed an "outperform" rating and issued a $47.00 price target on shares of Scholar Rock in a report on Thursday, January 9th. Truist Financial upped their target price on shares of Scholar Rock from $36.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, November 25th. HC Wainwright lifted their price objective on Scholar Rock from $40.00 to $50.00 and gave the company a "buy" rating in a report on Tuesday, November 26th. Finally, Piper Sandler raised their price target on Scholar Rock from $28.00 to $42.00 and gave the company an "overweight" rating in a report on Tuesday, October 15th.

Insider Activity at Scholar Rock

In other news, insider Jing L. Marantz sold 5,655 shares of the business's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $44.20, for a total value of $249,951.00. Following the completion of the transaction, the insider now owns 67,200 shares of the company's stock, valued at $2,970,240. The trade was a 7.76 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Public Equities L.P. Invus sold 409,433 shares of the firm's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $38.49, for a total value of $15,759,076.17. Following the sale, the insider now directly owns 10,850,005 shares in the company, valued at $417,616,692.45. The trade was a 3.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 458,974 shares of company stock worth $17,948,788. 19.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Scholar Rock

Institutional investors have recently modified their holdings of the business. Clearbridge Investments LLC bought a new position in shares of Scholar Rock during the second quarter worth about $6,223,000. Fisher Asset Management LLC boosted its stake in shares of Scholar Rock by 593.6% during the 3rd quarter. Fisher Asset Management LLC now owns 734,019 shares of the company's stock worth $5,879,000 after buying an additional 628,186 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Scholar Rock by 159.2% during the 2nd quarter. Millennium Management LLC now owns 925,584 shares of the company's stock worth $7,710,000 after buying an additional 568,512 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Scholar Rock by 1,051.3% in the 2nd quarter. Marshall Wace LLP now owns 487,285 shares of the company's stock valued at $4,059,000 after acquiring an additional 444,961 shares in the last quarter. Finally, FMR LLC raised its holdings in Scholar Rock by 3.1% during the third quarter. FMR LLC now owns 10,196,046 shares of the company's stock worth $81,670,000 after acquiring an additional 308,813 shares in the last quarter. Institutional investors own 91.08% of the company's stock.

Scholar Rock Stock Up 4.1 %

NASDAQ SRRK traded up $1.85 during trading on Wednesday, reaching $46.73. The company's stock had a trading volume of 1,514,020 shares, compared to its average volume of 1,048,055. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $4.37 billion, a PE ratio of -19.89 and a beta of 0.52. Scholar Rock has a 1-year low of $6.76 and a 1-year high of $46.81. The business has a 50-day moving average price of $40.33 and a 200-day moving average price of $23.75.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.